MTVA ▼ -5.1% - MetaVia Inc. $MTVA MTVA - MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction MetaVia shares declined 5.1% today following the company's announcement of preclinical findings that support the biological rationale for its DA-1726 compound to reduce waist circumference. While the positive preclinical data would typically support a therapeutic candidate's development pathway, the market's negative reaction suggests investors may have viewed the announcement as incrementally limited or were disappointed by the scope or timing of the results relative to expectations. 09-SEP-2026 08:02 AM ET